|Tested species reactivity||Dog, Hamster, Human, Mouse, Rat|
|Published species reactivity||Rat, Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic Peptide: R(5) V Q P E A Q A K V D V F R E D L C(22)|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS with 1mg/ml BSA|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||1 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 5 publications below|
PA1-960 detects proteasome activator 11S REG alpha subunit from canine, hamster, human, mouse and rat tissues and cells.
PA1-960 has been successfully used in Western blot procedures. By Western blot, this antibody detects a 28 kDa protein representing 11S REG alpha subunit in rat brain extract.
PA1-960 immunizing peptide corresponds to amino acid residues 5-22 of human proteasome activator 11S REG alpha. This sequence differs from the mouse and rat 11S REG alpha protein by a single amino acid residue. PA1-960 immunizing peptide (Cat. # PEP-097) is available for use in neutralization and control experiments.
Proteolytic degradation is critical to the maintenance of appropriate levels of short-lived and regulatory proteins as important and diverse as those involved in cellular metabolism, heat shock and stress response, antigen presentation, modulation of cell surface receptors and ion channels, cell cycle regulation, transcription, and signalling factors. The ubiquitin-proteasome pathway deconstructs most proteins in the eukaryotic cell cytosol and nucleus. Others are degraded via the vacuolar pathway which includes endosomes, lysosomes, and the endoplasmic reticulum.
The 26S proteasome is an ATP-dependent, multisubunit (~31), barrel-shaped molecular machine with an apparent molecular weight of ~2.5 MDa. It consists of a 20S proteolytic core complex which is crowned at one or both ends by 19S regulatory subunit complexes. The 19S regulatory subunits recognize ubiquitinated proteins and play an essential role in unfolding and translocating targets into the lumen of the 20S subunit. An enzymatic cascade is responsible for the attachment of multiple ubiquitin molecules to lysine residues of proteins targeted for degradation. Several genetic diseases are associated with defects in the ubiquitin-proteasome pathway. Some examples of affected proteins include those linked to cystic fibrosis, Angelman and quote;s syndrome, and Liddle syndrome.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Heterogeneous nuclear ribonucleoprotein A2 participates in the replication of Japanese encephalitis virus through an interaction with viral proteins and RNA.
PA1-960 was used in western blot to investigate the interaction between heterogeneous nuclear ribonucleoprotein A2 and the Japanese encephalitis virus core protein and its involvement in viral replication
|Katoh H,Mori Y,Kambara H,Abe T,Fukuhara T,Morita E,Moriishi K,Kamitani W,Matsuura Y||Journal of virology (85:10976)||2011|
Characterization of the Brain 26S Proteasome and its Interacting Proteins.
PA1-960 was used in western blot to detect the change in the proteasome-associated protein PA28alpha after NMDA exposure
|Tai HC,Besche H,Goldberg AL,Schuman EM||Frontiers in molecular neuroscience (3:null)||2010|
Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model.
PA1-960 was used in western blot to study the role of proteasome in a traumatic brain injury
|Yao X,Liu J,McCabe JT||Journal of neurochemistry (104:353)||2008|
Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies.
PA1-960 was used in western blot to investigate the changes of UCHL-1 in samples from dementia patients with Lewy bodies
|Barrachina M,Castaño E,Dalfó E,Maes T,Buesa C,Ferrer I||Neurobiology of disease (22:265)||2006|
Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
PA1-960 was used in western blot to investigate the role of the proteasome during the pathogenesis of R6/2 Huntington's disease.
|Bett JS,Goellner GM,Woodman B,Pratt G,Rechsteiner M,Bates GP||Human molecular genetics (15:33)||2006|